Stiris Research Inc. awarded a Phase I Healthy Volunteer study in Parkinson’s disease

Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announced that they have has entered into a second work order (the “WO”) with a US client to conduct their Phase I, Healthy Volunteer study in Parkinson’s disease.

This product is an orally administered, potent and selective inhibitor of the adenosine 2a receptor and has the potential to be the first new treatment modality for Parkinson’s disease in more than 20 years.

Parkinson’s disease is the second most common neurodegenerative disorder that affects predominantly dopamine-producing (“dopaminergic”) neurons in the substantia nigra area of the brain. In addition to movement-related (“motor”) symptoms, Parkinson’s symptoms may be unrelated to movement (“non-motor”) and can impact patients mental health and cause cognitive impairment (www.Parkinson.org).

“We are excited for the opportunity to continue to work in this interesting area of neurodegenerative disorders and have an impact on finding new treatment options for patients with Parkinson’s disease. Stiris’ why is about improving the lives of others, and this type of research is why we do what we do,” Amanda Carrera, Vice President, Stiris Research.